Predictive Biosciences plans to use its now-completed $25 million Series C round to begin commercializing its biomarker-based bladder cancer test. Predictive Biosciences completed a $25 million Series C round, saying it plans to use the money to complete clinical trials for its CertNDx bladder cancer assay and ready it for market. The assay reduces the […]
It plans to use the money to expand and market it Health Earnings System, which provides insurance for self-insured empoyers and offers rewards to employees who take part in certain health programs and guidelines. The company promises that anyone who "actively participates" in its health program "regardless of current health condition" pays less for their health care.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.